| Year |
Citation |
Score |
| 2024 |
Green HM, Manning JJ, Greig IR, Ross RA, Finlay DB, Glass M. Positive allosteric modulation of the cannabinoid CB receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics. British Journal of Pharmacology. PMID 38831545 DOI: 10.1111/bph.16433 |
0.801 |
|
| 2024 |
Manning JJ, Finlay DB, Glass M. GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the cannabinoid CB receptor and the consequences on G protein signalling. Biochemical Pharmacology. 224: 116190. PMID 38604257 DOI: 10.1016/j.bcp.2024.116190 |
0.783 |
|
| 2024 |
Patel M, Zheng X, Akinfiresoye LR, Prioleau C, Walker TD, Glass M, Marusich JA. Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists. European Journal of Pharmacology. 176549. PMID 38561104 DOI: 10.1016/j.ejphar.2024.176549 |
0.488 |
|
| 2024 |
Green HM, Fellner DMJ, Finlay DB, Furkert DP, Glass M. Determination of the Cannabinoid CB1 Receptor's Positive Allosteric Modulator Binding Site through Mutagenesis Studies. Pharmaceuticals (Basel, Switzerland). 17. PMID 38399369 DOI: 10.3390/ph17020154 |
0.352 |
|
| 2024 |
Green HM, Yang L, Zhu X, Finlay DB, Duffull SB, Glass M. Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 38227196 DOI: 10.1007/s00210-023-02923-6 |
0.465 |
|
| 2023 |
Yang L, Finlay DB, Green HM, Zhu X, Glass M, Duffull S. A quantitative pharmacology model for cannabinoid receptor type 1 (CB ) mediated by Gi/Gs protein competition. British Journal of Pharmacology. PMID 38072805 DOI: 10.1111/bph.16293 |
0.436 |
|
| 2023 |
Yang L, Zhu X, Finlay DB, Green H, Glass M, Duffull SB. A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid receptor (CB ). British Journal of Pharmacology. PMID 37277184 DOI: 10.1111/bph.16158 |
0.478 |
|
| 2023 |
Finlay DB, Mackie W, Webb HDJ, Thomsen LR, Nimick M, Rosengren RJ, Marusich JA, Glass M, Wiley JL. The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism. Pharmacology, Biochemistry, and Behavior. 223: 173530. PMID 36805861 DOI: 10.1016/j.pbb.2023.173530 |
0.469 |
|
| 2022 |
Webb HDJ, Finlay DB, Chen S, Vernall AJ, Sparkes E, Banister SD, Rosengren RJ, Glass M. Characterisation of AMB-FUBINACA metabolism and CB-mediated activity of its acid metabolite. Forensic Toxicology. 41: 114-125. PMID 36652070 DOI: 10.1007/s11419-022-00649-3 |
0.336 |
|
| 2022 |
Manning JJ, Rawcliffe G, Finlay DB, Glass M. Cannabinoid type-1 receptor arrestin subtype-selectivity and phosphorylation dependence. British Journal of Pharmacology. PMID 36250246 DOI: 10.1111/bph.15973 |
0.769 |
|
| 2022 |
Sparkes E, Boyd R, Chen S, Markham JW, Luo JL, Foyzun T, Zaman H, Fletcher C, Ellison R, McGregor IS, Santiago MJ, Lai F, Gerona RR, Connor M, Hibbs DE, ... ... Glass M, et al. Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs. Frontiers in Psychiatry. 13: 1010501. PMID 36245876 DOI: 10.3389/fpsyt.2022.1010501 |
0.435 |
|
| 2022 |
Kevin RC, Mirlohi S, Manning JJ, Boyd R, Cairns EA, Ametovski A, Lai F, Luo JL, Jorgensen W, Ellison R, Gerona RR, Hibbs DE, McGregor IS, Glass M, Connor M, et al. Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca3) Inhibitors. Acs Chemical Neuroscience. PMID 35442021 DOI: 10.1021/acschemneuro.1c00822 |
0.77 |
|
| 2022 |
Markham J, Sparkes E, Boyd R, Chen S, Manning JJ, Finlay D, Lai F, McGregor E, Maloney CJ, Gerona RR, Connor M, McGregor IS, Hibbs DE, Glass M, Kevin RC, et al. Defining Steric Requirements at CB and CB Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. Acs Chemical Neuroscience. 13: 1281-1295. PMID 35404067 DOI: 10.1021/acschemneuro.2c00034 |
0.783 |
|
| 2022 |
Finlay DB, Nguyen T, Gamage TF, Chen S, Barrus DG, Patel PR, Thomas BF, Wiley JL, Zhang Y, Glass M. Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Research & Perspectives. 10: e00901. PMID 35041297 DOI: 10.1002/prp2.901 |
0.542 |
|
| 2021 |
Sparkes E, Cairns EA, Kevin RC, Lai F, Grafinger KE, Chen S, Deventer MH, Ellison R, Boyd R, Martin LJ, McGregor IS, Gerona RR, Hibbs DE, Auwärter V, Glass M, et al. Structure-activity relationships of valine, -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. Rsc Medicinal Chemistry. 13: 156-174. PMID 35308023 DOI: 10.1039/d1md00242b |
0.458 |
|
| 2021 |
Patel M, Matti C, Grimsey NL, Legler DF, Javitch JA, Finlay DB, Glass M. Delineating the interactions between the cannabinoid CB receptor and its regulatory effectors; β-arrestins and G protein-coupled receptor kinases. British Journal of Pharmacology. PMID 34811740 DOI: 10.1111/bph.15748 |
0.639 |
|
| 2021 |
Ametovski A, Cairns EA, Grafinger KE, Cannaert A, Deventer MH, Chen S, Wu X, Shepperson CE, Lai F, Ellison R, Gerona R, Blakey K, Kevin R, McGregor IS, Hibbs DE, ... Glass M, et al. NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity? Acs Chemical Neuroscience. 12: 4020-4036. PMID 34676751 DOI: 10.1021/acschemneuro.1c00348 |
0.505 |
|
| 2021 |
Nguyen T, Gamage TF, Decker AM, Finlay DB, Langston TL, Barrus D, Glass M, Harris DL, Zhang Y. Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. Bioorganic & Medicinal Chemistry. 41: 116215. PMID 34015703 DOI: 10.1016/j.bmc.2021.116215 |
0.425 |
|
| 2021 |
Manning JJ, Green HM, Glass M, Finlay DB. Pharmacological Selection of Cannabinoid Receptor Effectors: Signalling, Allosteric Modulation and Bias. Neuropharmacology. 108611. PMID 34000272 DOI: 10.1016/j.neuropharm.2021.108611 |
0.785 |
|
| 2020 |
Ametovski A, Macdonald C, Manning JJ, Haneef SAS, Santiago M, Martin L, Sparkes E, Reckers A, Gerona RR, Connor M, Glass M, Banister SD. Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA. Acs Chemical Neuroscience. PMID 33054155 DOI: 10.1021/acschemneuro.0c00591 |
0.776 |
|
| 2020 |
Mielnik CA, Sugamori KS, Finlay DB, Thorpe HHA, Schapira M, Sivananthan N, Li CK, Lam VM, Harrington S, Abdelrahman MH, Trembleau LA, McIntyre Burnham W, Khokhar JY, Salahpour A, Ramsey AJ, ... Glass M, et al. A novel allosteric modulator of the cannabinoid CB receptor ameliorates hyperdopaminergia endophenotypes in rodent models. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 33036015 DOI: 10.1038/s41386-020-00876-5 |
0.374 |
|
| 2020 |
Narayan P, Reid S, Scotter EL, McGregor AL, Mehrabi NF, Singh-Bains MK, Glass M, Faull RLM, Snell RG, Dragunow M. Inconsistencies in histone acetylation patterns among different HD model systems and HD post-mortem brains. Neurobiology of Disease. 146: 105092. PMID 32979507 DOI: 10.1016/j.nbd.2020.105092 |
0.421 |
|
| 2020 |
Zhu X, Finlay DB, Glass M, Duffull SB. Evaluation of the profiles of CB cannabinoid receptor signalling bias using joint kinetic modelling. British Journal of Pharmacology. PMID 32293708 DOI: 10.1111/bph.15066 |
0.481 |
|
| 2020 |
Gamage TF, Barrus DG, Kevin RC, Finlay DB, Lefever TW, Patel PR, Grabenauer MA, Glass M, McGregor IS, Wiley JL, Thomas BF. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology, Biochemistry, and Behavior. 172918. PMID 32247816 DOI: 10.1016/J.Pbb.2020.172918 |
0.487 |
|
| 2020 |
Patel M, Manning JJ, Finlay DB, Javitch JA, Banister SD, Grimsey NL, Glass M. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology. 113871. PMID 32088263 DOI: 10.1016/J.Bcp.2020.113871 |
0.809 |
|
| 2019 |
Grant PS, Kahlcke N, Govindpani K, Hunter M, MacDonald C, Brimble MA, Glass M, Furkert DP. Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes. Bioorganic & Medicinal Chemistry Letters. 126644. PMID 31564385 DOI: 10.1016/J.Bmcl.2019.126644 |
0.399 |
|
| 2019 |
Finlay DB, Manning JJ, Ibsen MS, Macdonald CE, Patel M, Javitch JA, Banister SD, Glass M. Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. Acs Chemical Neuroscience. PMID 31513380 DOI: 10.1021/Acschemneuro.9B00429 |
0.797 |
|
| 2019 |
Kevin RC, Anderson L, McGregor IS, Boyd R, Manning JJ, Glass M, Connor M, Banister SD. CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist. Frontiers in Pharmacology. 10: 595. PMID 31191320 DOI: 10.3389/fphar.2019.00595 |
0.803 |
|
| 2019 |
Ibsen MS, Finlay DB, Patel M, Javitch JA, Glass M, Grimsey NL. Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence. Frontiers in Pharmacology. 10: 350. PMID 31024316 DOI: 10.3389/Fphar.2019.00350 |
0.693 |
|
| 2019 |
Zhu X, Finlay DB, Glass M, Duffull SB. Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: CB cannabinoid receptor internalisation. British Journal of Pharmacology. PMID 30945265 DOI: 10.1111/bph.14684 |
0.326 |
|
| 2019 |
Banister SD, Kevin RC, Martin L, Adams A, Macdonald C, Manning JJ, Boyd R, Cunningham M, Stevens MY, McGregor IS, Glass M, Connor M, Gerona RR. The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogues. Drug Testing and Analysis. PMID 30838752 DOI: 10.1002/Dta.2583 |
0.764 |
|
| 2019 |
Zhu X, Finlay DB, Glass M, Duffull SB. An intact model for quantifying functional selectivity. Scientific Reports. 9: 2557. PMID 30796256 DOI: 10.1038/s41598-019-39000-z |
0.382 |
|
| 2019 |
Singh S, Oyagawa CRM, Macdonald C, Grimsey NL, Glass M, Vernall AJ. Chromenopyrazole-based High Affinity, Selective Fluorescent Ligands for Cannabinoid Type 2 Receptor. Acs Medicinal Chemistry Letters. 10: 209-214. PMID 30783505 DOI: 10.1021/acsmedchemlett.8b00597 |
0.355 |
|
| 2018 |
Cooper AG, Oyagawa CRM, Manning JJ, Singh S, Hook S, Grimsey NL, Glass M, Tyndall JDA, Vernall AJ. Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1)-one-3-carboxamide scaffold. Medchemcomm. 9: 2055-2067. PMID 30647881 DOI: 10.1039/c8md00448j |
0.799 |
|
| 2018 |
Banister SD, Adams A, Kevin RC, Macdonald C, Glass M, Boyd R, Connor M, McGregor IS, Havel CM, Bright SJ, Ventura M, Gil C, Barratt MJ, Gerona RR. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold hopping analogue of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Testing and Analysis. PMID 30151911 DOI: 10.1002/Dta.2491 |
0.362 |
|
| 2018 |
Cooper AG, MacDonald C, Glass M, Hook S, Tyndall JDA, Vernall AJ. Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment. European Journal of Medicinal Chemistry. 145: 770-789. PMID 29407590 DOI: 10.1016/j.ejmech.2017.11.076 |
0.512 |
|
| 2017 |
Ibsen MS, Connor M, Glass M. Cannabinoid CB1 and CB2 Receptor Signaling and Bias. Cannabis and Cannabinoid Research. 2: 48-60. PMID 28861504 DOI: 10.1089/can.2016.0037 |
0.475 |
|
| 2017 |
Priestley R, Glass M, Kendall D. Functional Selectivity at Cannabinoid Receptors. Advances in Pharmacology (San Diego, Calif.). 80: 207-221. PMID 28826535 DOI: 10.1016/bs.apha.2017.03.005 |
0.521 |
|
| 2017 |
Finlay DB, Cawston EE, Grimsey NL, Hunter MR, Korde A, Kiran Vemuri V, Makriyannis A, Glass M. Gαs signalling of the CB1 receptor and the influence of receptor number. British Journal of Pharmacology. PMID 28516479 DOI: 10.1111/Bph.13866 |
0.492 |
|
| 2017 |
Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N, Finlay D, MacDonald C, Chicca A, Gens MD, Stuart J, ... ... Glass M, et al. Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nature Communications. 8: 13958. PMID 28045021 DOI: 10.1038/Ncomms13958 |
0.408 |
|
| 2016 |
Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JB, Glass M, McGregor IS, Connor M, Kassiou M. The pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. Acs Chemical Neuroscience. PMID 27421060 DOI: 10.1021/acschemneuro.6b00137 |
0.357 |
|
| 2016 |
Hunter MR, Grimsey NL, Glass M. Sulfation of the FLAG epitope is affected by co-expression of G protein-coupled receptors in a mammalian cell model. Scientific Reports. 6: 27316. PMID 27273047 DOI: 10.1038/srep27316 |
0.41 |
|
| 2016 |
Glass M, Govindpani K, Furkert DP, Hurst DP, Reggio PH, Flanagan JU. One for the Price of Two…Are Bivalent Ligands Targeting Cannabinoid Receptor Dimers Capable of Simultaneously Binding to both Receptors? Trends in Pharmacological Sciences. PMID 26917061 DOI: 10.1016/J.Tips.2016.01.010 |
0.417 |
|
| 2015 |
Redmond WJ, Cawston EE, Grimsey NL, Stuart J, Edington AR, Glass M, Connor M. Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. British Journal of Pharmacology. PMID 26398720 DOI: 10.1111/bph.13341 |
0.317 |
|
| 2015 |
Cawston EE, Connor M, Di Marzo V, Silvestri R, Glass M. Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors. Journal of Medicinal Chemistry. 58: 5979-88. PMID 26203658 DOI: 10.1021/acs.jmedchem.5b00579 |
0.33 |
|
| 2015 |
Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. Acs Chemical Neuroscience. PMID 26134475 DOI: 10.1021/acschemneuro.5b00112 |
0.363 |
|
| 2015 |
Khajehali E, Malone DT, Glass M, Sexton PM, Christopoulos A, Leach K. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor. Molecular Pharmacology. 88: 368-79. PMID 26044547 DOI: 10.1124/mol.115.099192 |
0.48 |
|
| 2015 |
Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M. Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. Acs Chemical Neuroscience. PMID 25921407 DOI: 10.1021/acschemneuro.5b00107 |
0.45 |
|
| 2014 |
Dowie MJ, Grimsey NL, Hoffman T, Faull RL, Glass M. Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. Journal of Chemical Neuroanatomy. 59: 62-71. PMID 24978314 DOI: 10.1016/j.jchemneu.2014.06.004 |
0.487 |
|
| 2013 |
Graham ES, Woo KK, Aalderink M, Fry S, Greenwood JM, Glass M, Dragunow M. M1 muscarinic receptor activation mediates cell death in M1-HEK293 cells. Plos One. 8: e72011. PMID 24023725 DOI: 10.1371/Journal.Pone.0072011 |
0.534 |
|
| 2013 |
Cawston EE, Redmond WJ, Breen CM, Grimsey NL, Connor M, Glass M. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action. British Journal of Pharmacology. 170: 893-907. PMID 23937487 DOI: 10.1111/bph.12329 |
0.475 |
|
| 2013 |
Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, Brooker L, Goebel C, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M. The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. Acs Chemical Neuroscience. 4: 1081-92. PMID 23551277 DOI: 10.1021/cn400035r |
0.311 |
|
| 2011 |
Goodfellow CE, Graham SE, Dragunow M, Glass M. Characterization of NTera2/D1 cells as a model system for the investigation of cannabinoid function in human neurons and astrocytes. Journal of Neuroscience Research. 89: 1685-97. PMID 21674570 DOI: 10.1002/Jnr.22692 |
0.499 |
|
| 2011 |
Grimsey NL, Goodfellow CE, Dragunow M, Glass M. Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochimica Et Biophysica Acta. 1813: 1554-60. PMID 21640764 DOI: 10.1016/J.Bbamcr.2011.05.010 |
0.65 |
|
| 2010 |
Dowie MJ, Scotter EL, Molinari E, Glass M. The therapeutic potential of G-protein coupled receptors in Huntington's disease. Pharmacology & Therapeutics. 128: 305-23. PMID 20708032 DOI: 10.1016/j.pharmthera.2010.07.008 |
0.319 |
|
| 2010 |
Grimsey NL, Graham ES, Dragunow M, Glass M. Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: implications for therapeutics. Biochemical Pharmacology. 80: 1050-62. PMID 20599795 DOI: 10.1016/J.Bcp.2010.06.007 |
0.678 |
|
| 2009 |
Goodfellow CE, Glass M. Anandamide receptor signal transduction. Vitamins and Hormones. 81: 79-110. PMID 19647109 DOI: 10.1016/S0083-6729(09)81004-2 |
0.438 |
|
| 2008 |
Grimsey NL, Narayan PJ, Dragunow M, Glass M. A novel high-throughput assay for the quantitative assessment of receptor trafficking. Clinical and Experimental Pharmacology & Physiology. 35: 1377-82. PMID 18565191 DOI: 10.1111/J.1440-1681.2008.04991.X |
0.646 |
|
| 2008 |
Scotter EL, Narayan P, Glass M, Dragunow M. High throughput quantification of mutant huntingtin aggregates. Journal of Neuroscience Methods. 171: 174-9. PMID 18367250 DOI: 10.1016/J.Jneumeth.2008.02.007 |
0.418 |
|
| 2006 |
Graham ES, Ball N, Scotter EL, Narayan P, Dragunow M, Glass M. Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. The Journal of Biological Chemistry. 281: 29085-95. PMID 16864584 DOI: 10.1074/Jbc.M602516200 |
0.572 |
|
| 2006 |
Curtis MA, Faull RL, Glass M. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. Journal of Chemical Neuroanatomy. 31: 210-5. PMID 16533591 DOI: 10.1016/J.Jchemneu.2006.01.005 |
0.47 |
|
| 2005 |
Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Molecular Pharmacology. 67: 1697-704. PMID 15710746 DOI: 10.1124/mol.104.006882 |
0.47 |
|
| Show low-probability matches. |